NVS - Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact
- BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis oncology drugs in China outside of China's largest cities.
- Shanghai Ji Xing Pharma in-licensed China rights to a heart failure treatment from Cytokinetics of South San Francisco in a $400 million pact.
- Suzhou CStone Pharma reported its anti-PD-L1 monoclonal antibody was approved for first-line use in non-small cell lung cancer.
For further details see:
Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact